Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017

Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant influenza A(H3N2) viruses considered antigenically matched to the clade 3C.2a vaccine strain. Sequence analysis revealed substan...

Descripción completa

Detalles Bibliográficos
Autores principales: Skowronski, Danuta M, Chambers, Catharine, Sabaiduc, Suzana, Dickinson, James A, Winter, Anne-Luise, De Serres, Gaston, Drews, Steven J, Jassem, Agatha, Gubbay, Jonathan B, Charest, Hugues, Balshaw, Robert, Bastien, Nathalie, Li, Yan, Krajden, Mel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2017
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316907/
https://www.ncbi.nlm.nih.gov/pubmed/28205503
http://dx.doi.org/10.2807/1560-7917.ES.2017.22.6.30460
Descripción
Sumario:Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant influenza A(H3N2) viruses considered antigenically matched to the clade 3C.2a vaccine strain. Sequence analysis revealed substantial heterogeneity in emerging 3C.2a1 variants by province and over time. Adjusted VE was 42% (95% confidence interval: 18–59%) overall, with variation by province. Interim virological and VE findings reported here warrant further investigation to inform potential vaccine reformulation.

Ejemplares similares